Souza y Machorro M, Guisa CVM, Barriga SLD

Language: Spanish
References: 171
Page: 227-244
PDF size: 166.05 Kb.

ABSTRACT

The DAHD is a congenital syndrome of precocious beginning and modifiable genetic or neurological etiology for vital experiences. The socioeconomic condition, familiar variables, grade of instruction and aptitude to request and use medical attention, have influence in the disorder and his varied comorbidity. In fact, multiple etiologies, environmental circumstances, processes of the development and psychiatric disorders produce hyperactivity, impulsiveness and shortfalls of attention, which can be complicated or, to be reoriented therapeutically towards useful activities. For clinical purposes, the pretherapeutic evaluation of the DAHD is basic to the effect of discarding concomitant pathologies, as the behavioral, affective, anxious or dissocial processes, etc. and more specifically the self-medication that contributes to the production of the addictive-psychotropic syndromes. An active interaction has been documented between DAHD and abuse/addiction to psychotropics in children, young and adult population, where the suitable identification of risk factors could allow his opportune detection in the first affectation levels and reduce probably, his clinical expression with it, on having diminished the morbidity and improved the prognosis of the cases, in the long term. The antiaddictive multimodal therapeutics in patients with DAHD (and in a special way when addictive comorbidity exists already), needs fulfillment of goals, care of drug interactions, maintenance of a suitable therapeutic relation and etiopathogenic research for its possible corrective and preventive blockade. This comorbidity particularly difficult and relevant for itself, is due to his individual, familiar and social impact, and for claims a more specific and strong participation from the health staff, the authorities and all those involved.

REFERENCES

1. Faraone SV, Sergeant J, Gillberg CH, Biederman J. La prevalencia a nivel mundial del TDAH: ¿es éste un trastorno típico de Estados Unidos? World Psychiatry 2003; 1(2): 2.

2. Hoekstra P, Steenhuis MP, Troost P. Relative contribution of ADHD, obsessive-compulsive disorder and tic severity to social and behavioral problems in tic disorders. J Develop Behav Pediat 2004; 25(4): 272-9.

3. American Psychiatric Association. Diagnostical and Statistical Manual of Mental Disorders DSM-IV. 4th. Ed. Washington; 1995.

4. Safer A. Niños hiperactivos: diagnóstico y tratamiento. Madrid: Ed. Santillana; 1979.

5. Biederman J. Practical considerations in stimulant drug selection for the Attention- deficit/Hyperactivity Disorder Patient-Efficacy, potency and titration. Today’s Therapeutic Trends 2002; 20(4): 311-28.

6. Orjales VA. Déficit de atención con hiperactividad. Madrid: Ed. CEPE; 1998.

7. Popper CH, West SA. Trastorno por déficit de atención con hiperactividad. En: Hales RE, Yudofsky SC, Talbott JA. Tratado de psiquiatría. Tomo I. Cap. 23. 3a. Ed. Trastornos de inicio en la infancia, la niñez o la adolescencia. The American Psychiatric Press; 2002.

8. Souza y Machorro M. Diagnóstico y tratamiento de los síndromes adictivos. México: Editorial Ciencia y Cultura Latinoamérica; 2000.

9. Guisa CVM, Díaz Barriga SL, Souza y Machorro M. A propósito de la relación entre adicciones y delincuencia. Psiquiatría 2003; 19(1): 14-27.

10. Taylor E. El niño hiperactivo. Barcelona: Ed. Martínez Roca; 1991.

11. Souza y Machorro M. Educación, salud y adicciones. Rev Mex Neuroci 2003; 4(2): 91-3.

12. Crosbie J, Schachar R. El control inhibitorio deficiente como subgrupo del TDAH. Am J Psychiatry 2001; 158: 1455-9.

13. Souza y Machorro M. Análisis observacional de la constelación adicto-terapéutica. Simposio Personalidad y Adicciones. Sección Académica de Farmacodependencia y Alcoholismo. Congreso Regional Vicepresidencia Noroeste “Trastornos de la personalidad y su comorbilidad”. Asociación Psiquiátrica Mexicana, A. C. San Carlos, Guaymas, Sonora. 3-6 de junio, 2004.

14. Travella J. Síndrome de atención dispersa, hiperactividad e impulsividad en pacientes adultos (ADHD). ALCMEON 2001; 10(2): 5.

15. Biederman J, Faraone SV, Spencer T. Patters of psychiatric comorbidity, cognition and psychosocial functioning in adults with ADHA. Am J Psychiatry 1993; 150: 1792-8.

16. Roy-Byrne P, Scheele L, Brinkley J. Adult ADHD: assessment guidelines based on clinical presentation to a specialty clinic. Compr Psychiatry 1990; 31: 417-25.

17. Barkley RA. ADHD and the Nature of self-control. New York: Guilford Press; 1997, p. 17-20.

18. Rucklidge JJ, Kaplan BJ. Las atribuciones y percepciones en mujeres adolescentes con sintomatología de ADHD. J Clini Psychol 2000; 56(6): 711-22.

19. Casado S. ADH: déficit de atención con hiperactividad. Aspectos generales. Psicología.com 2002, 6(1): 17-22.

20. Teijeiro R. Trastorno por déficit de atención con hiperactividad, TDAH en adultos. Diagnóstico y tratamiento. Interpsiquis 2003.

21. Souza y Machorro M, Quijano BEM, Díaz Barriga SL, Guisa CVM, Lorenzo AS, Gaucín RR. Historia Clínica Psiquiátrica Codificada para Adicciones, HCCPA. Psiquiatría 1998; 14(1): 13-25.

22. Tagle OI, Mercado CG, Martínez AJ, Martínez MJ, Souza y Machorro M. Por qué profesionalizar la terapéutica de las adicciones. Psiquiatría 2000; 16(3): 110-6.

23. Souza y Machorro M. El personal de salud y el manejo de los síndromes adictivos. Liber@ddictus 2000; 30: 21-3.

24. Cantwell DP, Baker L. Issues in classification of child and adolescent psychopathology. J Am Acad Child Adolesc Psychiatry 1988; 27: 521-33.

25. Mayes SD, Crites DL, Bixler ED. Methylphenidate and ADHA: influence of age, IQ and neurodevelopmental status. Dev Med Child Neurol 1994; 36: 1099-107.

26. Boris M, Mandel FS. Foods and additives are common causes of the attention deficit hyperactive disorder in children. Ann Allergy 1994; 72: 462-68.

27. Satterfield JH, Satterfield BT, Cantwell DP. Three-year multimodality treatment study of 100 hyperactive boys. J Pediatrics 1981; 98: 650-5.

28. Anderson J, Williams S. DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. Arch Gen Psychiatry 1987; 44: 69-76.

29. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1996; 1(3): 147-61.

30. Weiss G. ADHD. Philadelphia: W.B. Saunders Company; 1992.

31. Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry 1988; 45: 1023-31.

32. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the U.S. Arch Gen Psychiatry 1994; 51: 8-19.

33. Kaminer Y. Clinical implications of the relationship between ADHD and psychoactive substance use disorders. Am J Addict 1992; 1: 257-64.

34. Wilens TE, Spencer T, Biederman J. Attention-deficit disorder with substance abuse. In: Brown T. Subtypes of attention-deficit disorders in children, adolescents, and adults. Washington, D.C.: American Psychiatric Press; 1996.

35. Schubiner H, Tzelepis A, Isaacson JH, Warbasse LH, Zacharek M, Musial J. The dual diagnosis of ADHD and substance abuse: case reports and literature review. J Clin Psychiatry 1995; 56(4): 146-50.

36. Levin FR, Kleber HD. ADHD and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry 1995; 2(5): 246-58.

37. Levin FR, Evans SM, Kleber HD. Practical guidelines for the treatment of substance abusers with adult ADHD. Psychiatr Serv 1999; 50(8): 1001-3.

38. Mannuzza S, Klein RG, Bessler A, Malloy P, Lapadula M. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50: 565-76.

39. Wilens TE. ADHD and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatric Clinics of North America 2004; 27(2):1-5.

40. Demilio L. Psychiatric syndromes in adolescent substance abusers. Am J Psychiatry 1989; 146: 1212-4.

41. Milin R, Halikas JA, Meller JE, Morse C. Psychopathology among substance abusing juvenile offenders. J Am Acad Child Adolesc Psychiatry 1991; 30(4): 569-74.

42. Hovens JG, Cantwell DP, Kiriakos R. Psychiatric comorbidity in 1994. Compr Psychiatry 1995; 33(4): 476-83.

43. Goodwin DW, Schulsinger F, Hermansen L, Guze SB, Winokur G. Alcoholism and the hyperactive child syndrome. J Nerv Ment Dis 1975; 160: 349-53.

44. Wilens T, Spencer T, Biederman J. Are attention deficit/hyperactivity disorder and the psychoactive substance use disorders really related? Harv Rev Psychiatry1995; 3: 260-2.

45. Wilens T. Alcohol and Other drug use and ADHD. Alcohol Health Res World 1998; 22(2): 127-30.

46. Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelley BJ. Prevalence of ADHD and conduct disorder among substance abusers. J Clin Psychiatry 2000; 61(4): 244-51.

47. Levin FR, Evans S, Kleber HD. Prevalence of adult ADHD among cocaine abusers seeking treatment. Drug Alcohol Depend 1998; 52: 15-25.

48. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. ADHD is associated with early-onset substance use disorders. J Nerv Ment Dis 1997; 185(8): 475-82.

49. Carroll KM, Rounsaville BJ. History and significance of childhood ADHD in treatment-seeking cocaine abusers. Compr Psychiatry 1993; 34: 75-82.

50. Levin FR, Evans SM, Rosenthal M, KLEBER HD. Psychiatric comorbidity in cocaine abusers in outpatient settings or a therapeutic community. Presented at the CPDD 1997 Annual Meeting. Nashville, TN, June 14-19, 1997.

51. Wilens T, Spencer T, Biederman J. Are ADHD and the psychoactive substance use disorders really related? Harv Rev Psychiatry 1995; 3: 260-2.

52. Biederman J, Wilens TE, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with ADHD: effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152(11): 1652-8.

53. Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, Addalli KA. Hyperactive boys almost grown up. Replication of psychiatric status. Arch Gen Psychiatry 1991; 48: 77-83.

54. Mannuzza S, Klein R, Bessler A, Malloy P, Lapadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155(4): 493-8.

55. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry 1985; 24: 211-20.

56. Biederman J, Wilens TE, Mick E. Effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152(11): 1652-8.

57. Lynskey M, Fergusson D. Childhood conduct problems, attention-deficit behaviors and adolescent alcohol, tobacco, and illicit drug use. J Abnorm Child Psychol 1995; 23(3): 281-302.

58. Lambert N, Hartsough C, Sassone D, Sandoval J. Persistence of hyperactivity symptoms from childhood to adolescence and associated outcomes. Am J Orthopsychiatry 1987; 57(1): 22-32.

59. Blouin A, Bornstein R, Trites R. Teenage alcohol use among hyperactive children: a five year follow-up study. J Pediatr Psychol 1978; 3: 188-94.

60. Satterfield J, Hoppe C. A prospective study of delinquency in 110 adolescent boys with ADHD and 88 normal adolescent boys. Am J Psychiatry 1982; 139: 795-8.

61. Biederman J, Wilens T, Mick E, Faraone S, Weber W, Curtis S. Is DAHD a risk for psychoactive substance use disorder? Findings from a four-year follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36: 21-9.

62. Milberger S, Biederman J, Faraone S, Wilens T, Chu M. Associations between ADHD and psychoactive substance use disorders: findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997; 6: 318-29.

63. Wilens T, Faraone S, Biederman J, Gunawardene S. Does stimulant therapy of ADHD beget later substance abuse: a meta-analytic review of the literature? Pediatrics 2003; 11(1): 179-85.

64. Wilens T, Biederman J. Psychopathology in preadolescent children at high risk for substance abuse: a review of the literature. Harv Rev Psychiatry 1993; 1: 207-18.

65. Tarter RE, Edwards K. Psychological factors associated with the risk for alcoholism. Alcohol Clin Exp Res 1988; 12: 471-80.

66. Brook JS, Whiteman M, Cohen P, Shapiro J, Balka E. Longitudinally predicting late adolescent and young adult drug use: childhood and adolescent precursors. J Am Acad Child Adolesc Psychiatry 1995; 34(9): 1230-8.

67. Block J, Block JH, Keyes S. Longitudinally foretelling drug usage in adolescence: early childhood personality and environmental precursors. Child Dev 1988; 59: 336-55.

68. Kandel D, Faust R. Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiatry 1975; 32: 923-32.

69. Kandel DB, Logan JA. Patterns of drug use from adolescence to young adulthood: I. Periods of risk for initiation, continued use, and discontinuation. Am J Public Health 1984; 74: 660-6.

70. Milberger S, Biederman J, Faraone S, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36: 37-43.

71. Pomerleau O, Downey K, Stelson F, Pomerleau C. Cigarette smoking in adult patients diagnosed with ADHD. J Subst Abuse 1995; 7: 373-8

72. Biederman J. Pharmacotherapy for ADHD decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 2003; 64(Suppl 11): 3-8.

73. Biederman J, Faraone SV, Monuteaux MC, Feighner JA. Patterns of alcohol and drug use in adolescents can be predicted by parental substance use disorders. Pediatrics 2000; 106(4): 792-7.

74. Hechtman L, Weiss G. Controlled prospective 15-year follow-up of hyperactives as adults: non-medical drug and alcohol use and antisocial behaviour. Can J Psychiatry 1986; 31: 557-67.

75. Wilens T, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 1998; 7: 156-63.

76. Chassin L, Rogosch F, Barrera M. Substance use and symptomatology among adolescent children of alcoholics. J Abnorm Psychol 1991; 100(4): 449-63.

77. Sher KJ, Walitzer KS, Wood PK, Brent EE. Characteristics of children of alcoholics: putative risk factors, substance use and abuse, and psychopathology. J Abnorm Psychol 1991; 100: 427-48.

78. Mathew RJ, Wilson WH, Blazer DG, George LK. Psychiatric disorder adult children of alcoholics: data from the Epidemiologic Catchment Area Project. Am J Psychiatry 1993; 150(5): 793-800.

79. Nunes EV, Weissman MM, Goldstein RB, McAvay G, Seracini AM, Verdeli H. Psychopathology in children of parents with opiate dependence and/or major depression. J Am Acad Child Adolesc Psychiatry 1998; 37(11): 1142-51.

80. Moss H, Vanyukov M, Majumder P, Kirisci L, Tarter R. Pre-pubertal sons of substance abusers: influences of parental and familial substance abuse on behavioral disposition, IQ, and school achievement. Addict Behav 1995; 20(3): 345-58.

81. Aronson H, Gilbert A. Preadolescent sons of male alcoholics. Arch Gen Psychiatry 1963; 8: 235-41.

82. Fine EW, Yudin LW, Holmes J, Heinemann S. Behavioral disorders in children with parental alcoholism. Ann N Y Acad Sci 1976; 273: 507-17.

83. Steinhausen H, Gobel D, Nestler V. Psychopathology in the offspring of alcoholic parents. J Am Acad Child Adolesc Psychiatry 1984; 23: 465-71.

84. Wilens TE. The children and adolescent offspring of alcoholic parents. Curr Opin Psychiatry 1994; 7: 319-23.

85. Stanger C, Higgins S, Bickel W, Elk R, Grabowski J, Schmitz J. Behavioral and emotional problems among children of cocaine- and opiate- dependent parents. J Am Acad Child Adolesc Psychiatry 1999; 38(4): 421-8.

86. Earls F, Reich W, Jung KG, Cloninger CR. Psychopathology in children of alcoholic and antisocial parents. Alcohol Clin Exp Res 1988; 12(4): 481-7.

87. Wilens T, Hahesy A, Biederman J, Bredin B, Tanguay S, Monuteaux MC. Influence of parental SUD and ADHD on ADHD in their offspring. Preliminary results from a pilot controlled family study. Am J Addict 2000; 9:137-9.

88. Wilens T, Biederman J, Mick E, Faraone SV, Spencer T. ADHD is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475-82.

89. Biederman J, Faraone SV, Keenan K, Knee D, Tsuang MT. Family-genetic and psychosocial risk factors in DSM-III ADHD. J Am Acad Child Adolesc Psychiatry 1990; 29: 526-33.

90. Milberger S, Faraone S, Biederman J, Chu M, Wilens T. Familial risk analysis of the association between ADHD and psychoactive substance use disorders. Arch Pediatric Adolesc Med 1998; 152: 945-51.

91. Griffith DR, Azuma SD, Chasnoff IJ. Three-year outcome of children exposed pre-natally to drugs. J Am Acad Child Adolesc Psychiatry 1994; 33: 20-7.

92. Richardson GA, Day NL. Detrimental effects of prenatal cocaine exposure: illusion or reality? J Am Acad Child Adolesc Psychiatry 1994; 33: 28-34.

93. Volpe JJ. Effect of cocaine use on the fetus. N Engl J Med 1992; 327: 399-406.

94. Abel EL, Sokol RJ. Alcohol consumption during pregnancy: the dangers of moderate drinking. In: Goedde HW, Agarwal DP (Eds.). Alcoholism: biomedical and genetic aspects. Oxford: Pergamon Press; 1989.

95. Finnegan LP. Clinical effects of pharmacologic agents on pregnancy, the fetus and the neonate. Ann N Y Acad Sci 1976; 281: 74-89.

96. Steinhausen HC, Willms J, Spohr HL. Long-term psychopathological and cognitive outcome of children with fetal alcohol syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32: 990-4.

97. Merikangas K, Stolar M, Stevens D, Goulet J, Preisig M, Fenton B. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55(11): 973-9.

98. Tsuang MT, Lyons MJ, Eisen SA, G Oldberg J, True W, Lin N. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 1996; 67(5): 473-7.

99. Kaplan HI; Sadock BJ; Grebb JA. Synopsis of psychiatry. 7th. Ed. Washington: William & Wilkins; l994.

100. Mannuzza S, Gittelman-Klein R, Konig PH, Giampino TL. Hyperactive boys almost grown up: IV. Criminality and its relationship to psychiatric status. Arch Gen Psychiatry 1989; 46: 1073-9.

101. Souza y Machorro M. Por una psiquiatría de las adicciones. Rev Mex Neuroci 2003; 4(4): 206-8.

102. 102 Guisa CVM, Díaz Barriga SL, Souza y Machorro M. Una mirada reflexiva a la terapéutica de las adicciones. México: Dirección General. Centros de Integración Juvenil, A. C.; 2003.

103. Kaufman E. Diagnosis and treatment of drug and alcohol abuse in women. Am J Obstet Gynecol 1996; 174(1): 21-7.

104. Kaufman E, McNul J. Recent advances at the comprehension and treatment of drug abuse and dependence. Hosp Comm Psychiat 1992; 43(3): 220-32.

105. Souza y Machorro M. El papel de la mitología popular, la semántica y la iatrogenia en las adicciones. Rev Mex Neuroci 2001; 2(1): 25-7.

106. Souza y Machorro M. La deficiencia formativa del personal de salud y la terapéutica de las adicciones. Rev Mex Prev Readap Soc 2000; 8: 99-106.

107. Souza y MachorroM. Enseñanza e investigación en adicciones en la ciudad de México. Psiquiatría 1998; 14(3): 100-6.

108. Souza y Machorro M. Curso básico de adicciones. Centros de Integración Juvenil, A, C. Instituto de Asistencia e Integración Social, IASIS. Gobierno del Distrito Federal. México, Noviembre 11-15, 2002.

109. Organización Mundial de la Salud. Décima Revisión Internacional de la Clasificación de Enfermedades. Capítulo V. Desordenes mentales, conductuales y del desarrollo. Ginebra: OMS; 1993.

110. Olivares HM, Tagle OI, Mercado CG, Souza y Machorro M. Psicodinamia y psicoterapia del paciente adicto. Psiquiatría 2003; 19(1): 28-38.

111. Souza y Machorro M, Martínez AJ, Martínez MJ, Mercado CG, Tagle OI. Craving, adicción etílica y terapéutica. Archivos de Neurociencias 2000; 5(4): 201-4.

112. Diario Oficial. Proyecto de Norma Oficial Mexicana NOM-168-SSA1-1998, del Expediente Clínico. Lunes 7 de Diciembre de 1998.

113. Dazord A, Gerin P, Iahns J, Andreoli A. Pretreatment and process measures in crisis intervention as predictors of outcome. Psychotherapy Research 1991; 1(2): 135-47.

114. Freud S. Obras completas. Madrid: Biblioteca Nueva; 1967.

115. Souza y Machorro M. El reto de la auténtica identificación social del alcoholismo. Rev Fac Med UNAM 1990; 33(3): 15-26.

116. Velasco FR. Alcoholismo: visión integral. 2a. Reimp. México: Ed. Trillas; 1997.

117. Karasu T, Steinmuller RI. Psychotherapeutics in medicine. New York: Ed. Grune & Stratton; 1978.

118. Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron 1998; 21(3): 467-76.

119. De Wit H. Individual differences in acute effects of drugs in humans: their relevance to risk for abuse. NIDA Res Monograph 1998; 169: 176-87.

120. Bellack L, Smmall L. Emergency psychotherapy and brief psychotherapy. 2nd Ed. New York: Grune & Stratton; 1978.

121. Crown S. Individual long term psychotherapy. In: Bloch S. Introduction to the psychotherapies. Oxford University Press, 1979.

122. Ehrenwald J. Psi phenomena in psychiatry and psychotherapy. In: Arieti S (Ed). New dimensions in psychiatry: a world wide view. Vol. 2. New York: Wiley & Sons; 1977.

123. Musachio A. Dependencia y objeto totalitario. Factores psicológicos tempranos en la estructura de la personalidad adicta. Drogadicción. México: Paidós; 1996.

124. Casarino E. Desarrollo psicológico temprano y personalidad adicta. Temas de drogodependencia. Adicciones, Vol. II. Buenos Aires: Ed. Casasco; 1988.

125. Souza y Machorro M. Sociedad, enajenación y adicciones. Simposium adicciones, temas y reflexiones. II Reunión Nacional de la Federación de Sociedades Pro-Salud Mental. Oaxaca. Oax., 1997.

126. Souza y Machorro M. Adicciones, psicopatología y psicoterapia. Rev Mex Neuroci 2004; 5(1): 57-69.

127. Hartsough CS, Lambert NM. Pattern and progression of drug use among hyperactives and controls: a prospective short-term longitudinal study. J Child Psychol Psychiatry 1987; 28: 543-53.

128. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001; 49(3): 258-67.

129. Wilens T, Biederman J, Spencer T, Bostic J, Prince J, Monuteaux M. A pilot controlled clinical trial of Abt-418, a cholinergic agonist, in the treatment of adults with ADHD. Am J Psychiatry 1999; 156: 1931-7.

130. Lahoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N. Dopamine D4 receptor gene polymorphism is associated with ADHD. Mol Psychiatry 1996; 1: 121-4.

131. Faraone SV, Biederman J, Weiffenbach B, Keith T, Chu MP, Weaver A. Dopamine D4 gene 7-repeat allele and ADHD. Am J Psychiatry 1999; 156(5): 768-70.

132. Cook EH, Stein MA, Krasowski MD, Cox NJ. Association of ADHD and the dopamine transporter gene. Am J Hum Genet 1995; 56: 993-8.

133. Souza y Machorro M. Consideraciones y fundamentos para una terapéutica profesional de las adicciones. Rev Mex Neuroci 2003; 4(5): 326-30.

134. Comings D, Comings B, Muhleman D, Dietz G, Shahbahrami B, Tast D. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991; 266: 1793-800.

135. Ebstein R, Novick O, Umansky R, Priel B, Osher Y, Blaine D. Dopamine D4 exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 1996; 12: 78-80.

136. Souza y Machorro M. Modelos profesionales de tratamiento. Fundación de Investigaciones Sociales, A. C. Modelos de tratamiento para el alcoholismo. Cuadernos FISAC 2004: 25-46.

137. Souza y Machorro M. Nosología y terapéutica de los programas contra las adicciones. Dirección de Tratamiento. Centros de Integración Juvenil, A. C.

138. Conners C, Jett J. ADHD (in adults and children): the latest assessment and treatment strategies. Salt Lake City, UT: Compact Clinicals; 1999.

139. Brown T. Brown attention-deficit disorder scales. San Antonio, TX: The Psychological Corporation; 1996.

140. Millstein RB, Wilens TE, Biederman J, Spencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord 1997; 2(3): 159-66.

141. Carter RE, Edwards K. Psychological factors associated with the risk for alcoholism. Alcohol Clin Exp Res 1988; 12: 471-80.

142. Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37(3): 331-2.

143. Wilens T, McDermott S, Biederman J, Abrantes A, Hahesy A, Spencer T. Cognitive therapy in the treatment of adults with ADHD: a systematic chart review of 26 cases. J Cognit Psychother. An International Quarterly 1999; 13(3): 215-26.

144. McDermott SP, Wilens TE. Cognitive therapy for adults with ADHD. In: Brown T (Ed.). Subtypes of attention-deficit disorders in children, adolescents and adults. Washington, DC: American Psychiatric Press; 2000, p. 569-606.

145. Prochaska JO, Diclemente CC, Norcross JC. In search of how people change. Applications to addictive behaviour. Am Psychol 1992; 47: 1102-14.

146. Prochaska JO, Prochaska JM. Modelo transteorético de cambio para conductas adictivas. En: Casa M, Gossop M (Eds). Recaída y prevención de recaídas. Barcelona: Neurociencias; 1993, p. 85-136.

147. Beck A, Wright F, Newman C, Liese B. Terapia cognitiva de las drogodependencias. Barcelona: Paidos; 1999.

148. Wilens T. Drug therapy for adults with ADHD. Drugs 2003; 63(22): 2395-411.

149. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention deficit/hyperactivity disorder. J Addict Dis 2002; 21(2): 1-16.

150. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and ADHD: a pilot study. J Clin Psychopharmacol 2001; 21(1): 116-8.

151. Levin F, Evans S, McDowell D, Brooks D, Rhum M, Kleber H. Bupropion treatment for adult ADHD and cocaine abuse. Presented at the CPDD 1998 Annual Meeting. Scottsdale (AZ), June 13-18, 1998.

152. Prince J, Wilens T, Waxmonsky J, Hammerness P, Monuteaux M, Goldman S. An open study of sustained-release bupropion in adults with ADHD and substance use disorders. In: Scientific proceedings of the American Psychiatric Association. Philadelphia: New Clinical Drug Evaluation Unit (NCDEU); 2002; p. NR 222.

153. Schubiner H, Saules K, Arfken C, Johanson C, Schuster C, Lockhart N. Double-blind placebo controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286-94.

154. Levin FR, Evans SM, McDowell D, Kleber HD. Methylphenidate treatment for cocaine abusers with adult ADHD: a pilot study. J Clin Psychiatry 1997; 58: 1-21.

155. Drug Enforcement Administration. Methylphenidate review document. Washington, D.C.: Office of Diversion Control, Drug and Chemical Evaluation Section; 1995.

156. Jaffe SL. Failed attempts at intranasal abuse of concerta. J Am Acad Child Adolesc Psychiatry 2002; 41(1): 5.

157. Langer DH, Sweeney KP, Bartenbach DE, Davis PM, Menander KB. Evidence of Lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 1986; 17: 213-27.

158. Wilens TE, Biederman J, Spencer TJ. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997; 36: 45-8.

159. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence. Methylphenidate. J Clin Psychopharmacol 1997; 17(6): 485-8.

160. Shearer J, Wodak A, Mattick R, Van Beek I, Lewis JE, Hall WG. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001; 96: 1289-96.

161. Volkow ND, Ding Y, Fowler JS, Wang G, Logan J, Gatley JS. Is methylphenidate like cocaine? Arch Gen Psychiatry 1995; 52: 456-63.

162. Volkow N, Wang G, Fowler J, Gatley S, Logan J, Ding Y. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155(10): 1325-31.

163. Volkow N, Wang G, Fowler J, Hitzemann R, Angrist B. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addictions. Am J Psychiatry 1999; 156(1): 19-26.

164. Volkow ND, Wang GJ, Fowler JS, Logan G, Gerasimov M, Maynard L. Therapeutic doses of oral methylphenidate significantly increases extracellular dopamine in human brain. J Neurosci 2001; 21: 1-5.

165. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extra-cellular dopamine. Therapeutic implications. Synapse 2002; 43(3): 181-7.

166. Souza y Machorro M, Díaz Barriga LS, Guisa C VM. Adicciones: neuroquímica y terapéutica. México: Centros de Integración Juvenil, A. C.; 2004.

167. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with/without ADHD. Am J Addict 1998; 7 :156-63.

168. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475-82.

169. Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of ADHD and maternal smoking, alcohol use and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry 2002; 41(4): 17-34.

170. Biederman J, Wilens T, Mick E, Milberger S, Spencer T, Faraone S. Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652-8.

171. Biederman J, Wilens T, Mick E, Spencer T, Faraone V. Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatric 1999; 104(2): 1-5.